(A) Pre-treatment with AM630 reduces WIN-evoked CGRP release, while co-treatment of TG neurons with AM630 and WIN increase overall CGRP release. (B) Pre-treatment with AM251 does not affect WIN-evoked CGRP release, while co-treatment of neurons with AM251 and WIN substantially decreases overall CGRP release. Concentrations of drugs (AM251, AM630 and WIN) are indicated. Pre-treatment times with AM251 and AM630 are 15 min. WIN treatment and co-treatment with AM251 or AM630 was also for 15 min. Wash times 2 min each with two changes of Hanks solution, n = 6; error bars = SEM **p<0.01, ***p<0.001. (C) Co-treatment of WIN with indicated concentrations of AM630 increase overall CGRP release in a concentration-dependent fashion. (D) In contrast, co-treatment of WIN with indicated concentrations of AM251 decrease overall CGRP release in a concentration-dependent fashion, n = 6; error bars = SEM, *p<0.05, **p<0.01. “B” indicates baseline release of CGRP.